Planet BCE

UAS, C-UAS, Deep Space, DoD, NASA. KULR, "Space-based industries will vastly exceed the value of all of Earth" -Elon Musk

[Incannex Healthcare Inc. @ASX_IHL]

$IXHL is working to address patient needs in the expanding OSA market, where demand for treatment continues to grow.

This growth is being driven by greater public awareness, more frequent diagnoses and risk assessments, the impact of wearables and AI, and lifestyle factors including obesity and an aging population.

Learn more: https://t.co/uGyZ7BETmq

[Incannex Healthcare Inc. @ASX_IHL]

Check out our IHL-42X Clinical Advisory Board!

IHL-42X continues to advance with the recent commencement of the DReAMzz Clinical Study, while the recent U.S. patent grant significantly enhances its commercial value by protecting $IXHL’s proprietary oral combination therapy and supporting long-term market exclusivity.

Learn more: https://t.co/a7nRQwHgSg

[Incannex Healthcare Inc. @ASX_IHL]

$IXHL announced that the United States Patent and Trademark Office (USPTO) has granted a key patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea.”

The grant of this patent represents a significant milestone in the advancement of IHL-42X and materially strengthens Incannex’s intellectual property portfolio supporting its lead clinical program.

🔗 https://t.co/YuQ2mxkQbw

[Incannex Healthcare Inc. @ASX_IHL]

#ICYMI $IXHL recently announced that the @uspto has granted a key patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea.”

The strengthened U.S. patent position significantly enhances the commercial value of IHL-42X by protecting the Company’s proprietary oral combination therapy and supporting long-term market exclusivity.

🔗https://t.co/YuQ2mxkQbw

[Incannex Healthcare Inc. @ASX_IHL]

$IXHL is working on the development of innovative oral fixed-dose treatments and therapeutic regimens designed to address challenging chronic conditions.

By reducing the dose of each drug component, we aim to minimize side effects while maximizing patient benefit.

Learn more: https://t.co/z7bivwMKeQ

[KULR Technology @KULRTech]

$KULR has extended the pause of its ATM equity offering through September 30, 2026 -- protecting shareholders from dilution while prioritizing the scale-up of its KULR ONE® Space, Air and MAX platforms.

Read more here: https://t.co/NE0eJAKEUn

[Michael Mo @michaelmokulr]

Physical AI is moving fast.

As AI enters the real world through drones, robotics, and autonomous systems, safe high-performance energy systems become critical.

That’s where $KULR is focused. https://t.co/6H5taUHNzv

[jungle.java @junglejava1]

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

$IXHL $PSIL

https://t.co/R5OUe4Eek5

[Planet BCE @PlanetBCE]

$KULR

[TIGRESS🐯 @og_tigress]

$KULR nice article from the other day about securing prototype battery development contract with U.S.-based military drone manufacturer. They are working with a domestic mfg who is also part of the Drone Dominance Initiative.

"Under the agreement, KULR will execute system-level design, battery architecture development, prototype fabrication, functional and safety testing, certification support, and production-readiness activities for the customer’s UAV and ground control station platforms."

https://t.co/6T7PWYr5dc

[KULR Technology @KULRTech]

KULR Chairman, Founder, and CEO Michael Mo has released a new shareholder letter outlining the company’s strategy to power the physical AI era across space, defense, drones, AI data centers, and robotics.

Battery is infrastructure. KULR’s 2026 mission is clear: build more batteries and sell more batteries.

Read the letter here:
https://t.co/R4IzEvWLz4

[Planet BCE @PlanetBCE]

$IXHL Incannex is "nearing commencement of patient recruitment." Given the cIRB model and the status of the first site, we are likely looking at a window of 1–3 weeks before we see the "First Patient Dosed" announcement. Major Tailwinds coming. Congrats Team

[Incannex Healthcare Inc. @ASX_IHL]

$IXHL announced that the United States Patent and Trademark Office (USPTO) has granted a key patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea.”

The grant of this patent represents a significant milestone in the advancement of IHL-42X and materially strengthens Incannex’s intellectual property portfolio supporting its lead clinical program.

🔗 https://t.co/YuQ2mxkQbw

[Incannex Healthcare Inc. @ASX_IHL]

Innovating New Pathways to Relief.

$IXHL is dedicated to developing and delivering innovative medicines for people living with chronic diseases and significant unmet needs such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

Learn more about our clinical trials: https://t.co/z7bivwMKeQ

[Incannex Healthcare Inc. @ASX_IHL]

$IXHL is heading to SLEEP 2026 in Baltimore, June 14–17. Stop by our poster session presented by Mark Bleackley, Ph.D. and Lou Barbato, M.D. on Tuesday, June 16, 2026 from 11:00-11:45 AM:

“IHL-42X, A Proprietary Combination Product Containing Dronabinol and Acetazolamide, for Treatment of Obstructive Sleep Apnea”

Reach out if you’ll be attending and want to learn more about #IXHL.

[Incannex Healthcare Inc. @ASX_IHL]

#ICYMI $IXHL recently announced that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program.

Incannex continues to strengthen its balance sheet through disciplined capital management and strategic utilization of government innovation incentives.

Learn more: https://t.co/cpn6m7fgUD

[Incannex Healthcare Inc. @ASX_IHL]

IHL-42X is an oral fixed-dose combination therapy of acetazolamide and dronabinol currently in clinical studies and granted recent Fast Track Designation by the US_FDA.

$IXHL is dedicated to furthering IHL-42X as a potential first-in-class oral therapy for obstructive #sleepapnea.

🔗https://t.co/uGyZ7BETmq

[Incannex Healthcare Inc. @ASX_IHL]

$IXHL is heading to SLEEP 2026 in Baltimore, MD, June 14–17!

If you’re attending, be sure to catch our poster session presented by Mark Bleackley, Ph.D. and Lou Barbato, M.D. on June 16.

📄 IHL-42X, A Proprietary Combination Product Containing Dronabinol and Acetazolamide, for Treatment of Obstructive Sleep Apnea
📅 Tuesday, June 16, 2026 | 11:00-11:45 AM
📍 Poster Session P-41 | Board #520 | Baltimore Convention Center

Reach out to learn more!

[Michael Mo @michaelmokulr]

Orbital AI data centers won’t just be a compute challenge, they’ll be a power, thermal, battery safety, and reliability challenge.
https://t.co/iQr0ngODcl

[Incannex Healthcare Inc. @ASX_IHL]

$IXHL is pleased to announce that it has received A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program.

In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1million in R&D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under the program to more than A$11.1 million received in 2026.

🔗https://t.co/cpn6m7fgUD

[Planet BCE @PlanetBCE]

$IXHL Non Dilutive Capital Infusion
Brilliant

[Planet BCE @PlanetBCE]

$IXHL June 16 SLEEP conference presentation and end of fiscal year June 30 arriving fast

[Incannex Healthcare Inc. @ASX_IHL]

$IXHL is pleased to announce that Alliance Global Partners (“AGP”) has initiated equity research coverage of the Company.

The research report provides an independent assessment of Incannex’s clinical pipeline, development strategy, market opportunities and future growth prospects.

🔗 https://t.co/jker9MF0vO